Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986504 with Standard-of-Care in Metastatic MTAP-deleted Solid Tumors
NCT07532902Phase 1Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Apr 2026
- Primary completion
- Apr 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of MRTX1719 in pleural mesothelioma, gastroesophageal junction adenocarcinoma and urothelial carcinoma (UC) (3 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Recommended Phase II Dose at 2 years. Started Apr 2026; status: recruiting.
02
Drugs
MRTX1719
03
Conditions
pleural mesotheliomagastroesophageal junction adenocarcinomaurothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT07532902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07532902.